Trial record 1 of 1 for:
NCT02489539 | Recruiting, Not yet recruiting Studies
Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02489539 |
|
Recruitment Status :
Recruiting
First Posted : July 3, 2015
Last Update Posted : May 2, 2022
|
Sponsor:
W.L.Gore & Associates
Information provided by (Responsible Party):
W.L.Gore & Associates
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of the study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to treat an infrarenal aneurysm located in the abdominal aorta. Performance of the GORE® EXCLUDER® Conformable AAA Endoprosthesis will be judged by separate performance goals.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Aortic Aneurysm, Abdominal | Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis | Not Applicable |
The study design is a prospective, nonrandomized, international, multicenter study comprised of two parallel substudies. The total subject population will be 190 subjects with 80 subjects assigned to the Short Neck Substudy and 110 subjects to the High Neck Angulation Substudy.
This clinical study will include fifty-six sites in the US. Each enrolled subject will undergo periodic follow-up evaluations involving physical exams and contrast-enhanced computed tomography (CT) scans at specific, protocol-defined intervals for a period of five years following the GORE® EXCLUDER® Conformable AAA Endoprosthesis implant. Each Substudy will be evaluated and reported independently from each other according to the Safety and Effectiveness Endpoints. No comparative analyses between these substudies are planned.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 190 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms |
| Actual Study Start Date : | December 19, 2017 |
| Estimated Primary Completion Date : | December 30, 2022 |
| Estimated Study Completion Date : | December 31, 2026 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Short Neck Substudy
Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
|
Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis
Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique. |
|
Experimental: High Neck Angulation Substudy
Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation > 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
|
Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis
Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique. |
Primary Outcome Measures :
- Safety as measured by a composite of Adverse Events [ Time Frame: 30 Days ]
Composite of the following:
- Death
- Stroke
- Myocardial Infarction
- Bowel Ischemia
- Paraplegia
- Respiratory Failure
- Renal Failure
- Procedural Blood Loss > 1000 mL
- Thromboembolic events (including limb occlusion and distal embolic events)
- Effectiveness as measured by a composite of Adverse Events [ Time Frame: 12 Months ]
Composite of technical success (successful access and deployment of all required GORE® EXCLUDER® Conformable AAA Endoprosthesis components) and freedom from:
- Type I endoleak in the 12 month window
- Type III endoleak in the 12 month window
- Migration (10 mm or more) between the one month and at the 12 month window
- AAA enlargement ≥5 mm with or without intervention between the one month and the 12 month window
- AAA rupture through the 12 month window
- Conversion to open repair through the 12 month window
Secondary Outcome Measures :
- Reintervention [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Stent fracture based on core lab analysis [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Type II endoleak [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Aneurysm-related mortality [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Index Procedure Blood Loss [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Type IV endoleak [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Length of Hospital Stay (initial hospitalization) [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Index Procedure Time [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Stroke [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Myocardial Infarction [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Bowel Ischemia [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Paraplegia [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Death [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Renal Failure [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Respiratory Failure [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Thromboembolic events (including limb occlusion and distal embolic events) [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Type I endoleak [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Type III endoleak [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Migration (10 mm or more) [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Procedural Blood Loss > 1000 mL [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- AAA enlargement ≥5 mm with or without intervention [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- AAA rupture [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
- Conversion to open repair [ Time Frame: 12 Months ]Effectiveness as measured by a composite of Adverse Events
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
AAA meeting any of the following criteria:
- Maximum diameter ≥50 mm
- Rapid growth (>5 mm in a 6 month period)
- Non-ruptured AAA presenting with clinical symptoms
-
Adequate anatomy to receive the GORE® EXCLUDER® Conformable AAA Endoprosthesis, including:
- Adequate iliac / femoral access
- Infrarenal aortic neck diameter 16-32 mm
- Infrarenal aortic neck length ≥10 mm
- Aortic neck angle ≤ 90˚
- Distal iliac artery seal zone ≥10 mm
- Iliac artery diameter 8-25 mm
- An Informed Consent Form (ICF) signed by Subject
- Male or infertile female
- Able to comply with Protocol requirements including following-up
- Life expectancy > 2 years
- Age ≥ 21 years
Exclusion Criteria:
- Mycotic or ruptured aneurysm
- Known concomitant thoracic aortic aneurysm which requires surgical intervention
- Renal insufficiency defined as creatinine > 2.5 mg/dL or patient undergoing dialysis
- New York Heart Association (NYHA) class IV
- Aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s)
- Severely tortuous or stenotic iliac and / or femoral arteries
- Patient has body habitus or other medical condition which prevents adequate delineation of the aorta
- Participating in another investigational device or drug study within 1 year of treatment
- Systemic infection which may increase the risk of endovascular graft infection
- Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome
- Planned concomitant surgical procedure or major surgery within 30 days of treatment date
- Known history of drug abuse
- Known sensitivities or allergies to the device materials
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02489539
Contacts
| Contact: Jeannie Cunningham | 928-863-4797 | jecunnin@wlgore.com | |
| Contact: Chris Timberlake | 928-707-4974 | Ctimberl@wlgore.com |
Locations
Show 50 study locations
Sponsors and Collaborators
W.L.Gore & Associates
Investigators
| Principal Investigator: | Robert Rhee, MD | Maimonides Medical Center (US) |
| Responsible Party: | W.L.Gore & Associates |
| ClinicalTrials.gov Identifier: | NCT02489539 |
| Obsolete Identifiers: | NCT02489552 |
| Other Study ID Numbers: |
AAA 13-03 (1) |
| First Posted: | July 3, 2015 Key Record Dates |
| Last Update Posted: | May 2, 2022 |
| Last Verified: | April 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | Device and aneurysm status will be communicated to subject through standard of care evaluations. Core Lab data will not be available to subjects. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
Keywords provided by W.L.Gore & Associates:
|
Aortic aneurysm Abdominal aorta Stent graft |
Aneurysm Vascular Diseases Cardiovascular Diseases |
Additional relevant MeSH terms:
|
Aneurysm Aortic Aneurysm Aortic Aneurysm, Abdominal |
Vascular Diseases Cardiovascular Diseases Aortic Diseases |